201 results on '"Arrondeau J"'
Search Results
2. Les tumeurs thymiques
3. IHC, FISH, CISH, NGS dans les cancers bronchiques non à petites cellules : quelles évolutions dans l’ère des biomarqueurs ?
4. Actualités et perspectives concernant l’immunothérapie au cours des CBNPC
5. Relations entre fixation colique du 18FDG en TEP, dépense énergétique de repos et efficacité de l’immunothérapie chez des patients ayant un cancer pulmonaire non à petites cellules traités par immunothérapie : résultats préliminaires de l’étude MICROB
6. Étude des caractéristiques cliniques, histologiques et moléculaires associées à une forte expression de la proteine Programmed Death Ligand-1 (PD-L1) dans les adénocarcinomes du poumon métastatiques mutés EGFR (Epidermal Growth Factor Receptor)
7. Estimation of glomerular filtration rate in cancer patients with abnormal body composition and relation with carboplatin toxicity
8. 1136P Relationship between caloric intakes and sensitivity to immune checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients: The ELY-2 study
9. 1023P Relationship between 18F-FDG PET colonic uptake, resting energy expenditure and immune checkpoint inhibitors efficacy in metastatic non-small cell lung cancer (NSCLC) patients: Preliminary results of the MICROBIO-TEP study
10. 1073P Relationship between basal metabolism, nivolumab clearance and survival in metastatic non-small cell lung cancer patients of the ELY study
11. Brèves de l’AERIO
12. MA16.01 Subsequent Systemic Therapy After Lurbinectedin Discontinuation in Patients With Small-cell Lung Cancer
13. Brèves de l’AERIO
14. 1200P BrigALK2 study: A multicentric real-world study evaluating brigatinib in ALK positive advanced pre-treated non-small cell lung cancers: Long-term follow-up with focus on lorlatinib efficacy after brigatinib
15. Metformine et aspirine : de « nouveaux » traitements du cancer ?: Prévention et activité antitumorale
16. Congrès Targeted Anticancer Therapies — TAT 2013
17. Étude SCLERONCO-1 : Étude de tolérance et de pharmacovigilance des Immune Checkpoint Inhibiteurs chez les patients ayant une SCLERodermie systémique préexistante en ONCOlogie
18. L’index de sarcopénie est un marqueur de survie globale chez les patients atteints de cancer
19. Brèves de l’AERIO: Un an versus trois ans de traitement adjuvant par imatinib pour les tumeurs stromales gastro-intestinales opérables
20. MO01.09 Phase 2 Basket Trial of Lurbinectedin in Small-Cell Lung Cancer (SCLC): Analysis of Efficacy by Baseline Characteristics
21. Le nivolumab augmente la pression artérielle pulmonaire chez les patients traités pour carcinome pulmonaire non à petites cellules
22. MO01.10 Activity of Lurbinectedin in Second-line SCLC Patients Who Are Candidates for Platinum Rechallenge
23. Bi-weekly very-high-dose lapatinib: an easy-to-use active option in HER-2-positive breast cancer patients with meningeal carcinomatosis
24. Étude SCLERONCO-1 : étude de tolérance et de pharmacovigilance des Immune Checkpoint Inhibiteurs chez les patients ayant une SCLERodermie systémique préexistante en ONCOlogie
25. Prognostic value of the nutritional status in patients with metastatic non-small cell lung cancer treated with immune checkpoints inhibitors
26. 1392P Brigatinib in patients with ALK-positive advanced non-small cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study)
27. 1784P Activity of lurbinectedin in second-line SCLC patients candidates for platinum re-challenge
28. 1048P Should I stay or should I go: Optimal duration for antiPD(L)1 therapy
29. 1396P Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM cohort: The ELY study
30. P1.12-03 Antitumor Activity of Single Agent Lurbinectedin in Patients with Relapsed SCLC Occurring ≥30 Days After Last Platinum Dose
31. Efficacité et tolérance du brigatinib chez des patients pris en charge pour un cancer bronchopulmonaire non à petites cellules avec translocation ALK en France. Étude BRIGALK
32. P1.13-09 Efficacy and Tolerance of Osimertinib in Real Word Setting: Results of the French Early Access Program (EXPLORE T790M GFPC Study)
33. Characterizing the risk of drug-drug interactions in sarcoma treated patients: Role of pharmacist integration
34. Hepatic metastasis from basal cell carcinoma: A rare location with an unreported presentation
35. Nivolumab combined with ruxolitinib: antagonism or synergy?
36. Hepatic and renal tolerance of immune checkpoint inhibitors for cancer treatment: A retrospective monocentric cohort study
37. Abstract P4-06-06: Consistent dosing-time dependent tolerability of everolimus (EV) in a pilot study in women with metastatic breast cancers (MBC) and in a mouse chronopharmacology investigation
38. La sarcopénie associée à un IMC>25kg/m2 est prédictive de toxicité sévère précoce sous anti-PD1 chez les patients atteints de mélanome
39. Une histoire naturelle lente est associée à un meilleur taux de réponse aux anti-PD1 dans le mélanome
40. Sarcopenia associated with a body mass index (BMI) > 25 kg/m2 predicts severe acute toxicity of nivolumab and pembrolizumab in melanoma patients
41. Estimation of glomerular filtration rate in patients with abnormal body composition and relation with carboplatin toxicity
42. Evaluation of the interindividual variability in plasma nivolumab level in non-small-lung cancer outpatients: preliminary results
43. Identification of patients at risk for severe toxicity under PD1 inhibitors: role of sarcopenic overweight
44. Slow natural history predicts higher response rate to nivolumab and pembrolizumab in advanced melanoma patients
45. 1632P_PR - Characterizing the risk of drug-drug interactions in sarcoma treated patients: Role of pharmacist integration
46. Une délétion complète du gène codant pour la ménine révélée par un carcinome neuroendocrine thymique
47. Hypermétabolisme, cachexie et toxicité des traitements anti-tumoraux : étude prospective chez 277 patients atteints de cancer
48. FRI-512 - Hepatic and renal tolerance of immune checkpoint inhibitors for cancer treatment: A retrospective monocentric cohort study
49. 3451 Insulin-resistance in sarcoma patients: analysis of a prospective cohort
50. 1319 A prevalence study of drug-drug interactions in metastatic prostate cancer patients receiving abiraterone
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.